Clinical trial
Study of Oral Fampridine-SR in Multiple Sclerosis
NCT00127530 · Acorda Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00127530 |
|---|---|
| Title | Study of Oral Fampridine-SR in Multiple Sclerosis |
| Official title | Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis |
| Lead sponsor | Acorda Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Fampridine-SR, Placebo |
| Enrollment | 300 |
| Start date | May 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Aug 8, 2005 |
| Last update posted | Sep 11, 2018 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: